Literature DB >> 33714852

Korea National Stem Cell Bank.

Jung-Hyun Kim1, Hye-Yeong Jo2, Hye-Yeong Ha2, Yong-Ou Kim2.   

Abstract

The Korea National Stem Cell Bank has been banking pluripotent stem cell (PSC) lines since 2012. Quality-controlled and ethically sourced cell lines were developed for distribution. Currently (as of 2020), among the 69 deposited lines, 4 research-grade human embryonic stem cell (hESC) lines and 19 induced pluripotent stem cell (iPSC) lines have been distributed. Good manufacturing practices (GMP)-compliant homozygous iPSC lines for regenerative medicine with homozygous HLA haplotypes that cover 51% of the Korean population have been deposited as well. To ensure the quality of the cell lines, we performed eighteen different quality tests on the identity, sterility, consistency, stability and safety of the cell lines. Regarding genetic stability, we are collecting SNPchip, WES, Methyl-seq, and RNA-seq data, which are open to the public.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2021        PMID: 33714852     DOI: 10.1016/j.scr.2021.102270

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  4 in total

Review 1.  Dental applications of induced pluripotent stem cells and their derivatives.

Authors:  Pan Gao; Shan Liu; Xiaoyi Wang; Makoto Ikeya
Journal:  Jpn Dent Sci Rev       Date:  2022-04-30

2.  Correlation Between Genetic Abnormalities in Induced Pluripotent Stem Cell-Derivatives and Abnormal Tissue Formation in Tumorigenicity Tests.

Authors:  Takako Yamamoto; Yoji Sato; Satoshi Yasuda; Masayuki Shikamura; Takashi Tamura; Chiemi Takenaka; Naoko Takasu; Masaki Nomura; Hiromi Dohi; Masayo Takahashi; Michiko Mandai; Yonehiro Kanemura; Masaya Nakamura; Hideyuki Okano; Shin Kawamata
Journal:  Stem Cells Transl Med       Date:  2022-05-27       Impact factor: 7.655

3.  Single-Cell RNA Sequencing of Human Pluripotent Stem Cell-Derived Macrophages for Quality Control of The Cell Therapy Product.

Authors:  Hye-Yeong Jo; Hyang-Hee Seo; Dayeon Gil; YoungChan Park; Hyeong-Jun Han; Hyo-Won Han; Rajesh K Thimmulappa; Sang Cheol Kim; Jung-Hyun Kim
Journal:  Front Genet       Date:  2022-01-31       Impact factor: 4.599

4.  Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies.

Authors:  Jung-Hyun Kim; Eihachiro Kawase; Kapil Bharti; Ohad Karnieli; Yuji Arakawa; Glyn Stacey
Journal:  NPJ Regen Med       Date:  2022-09-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.